QLS4131 Combination Therapy in Malignant Plasma Cell Neoplasms

NCT07560449 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

162

Enrollment

INDUSTRY

Sponsor class

Conditions

Malignant Plasma Cell Neoplasms

Interventions

DRUG: QLS4131
DRUG: QL2109
DRUG: Pomalidomide
DRUG: Lenalidomide
DRUG: Dexamethasone

Sponsor

Qilu Pharmaceutical Co., Ltd.